| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Division of Surgical Oncology, Department of Surgery, and
Neurosurgery Service, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
1Correspondence: Division of Surgical Oncology, Massachusetts General Hospital, Cox 626, 100 Blossom St., Boston, MA 02114 USA.
Viruses used for gene therapy are usually genetically modified to deliver therapeutic transgenes and prevent viral replication. In contrast, replication-competent viruses may be used for cancer therapy because replication of some viruses within cancer cells can result in their destruction (oncolysis). Viral ribonucleotide reductase expression is defective in the HSV1 mutant hrR3. Cellular ribonucleotide reductase, which is scarce in normal liver and abundant in liver metastases, can substitute for its viral counterpart to allow hrR3 replication in infected cells. Two or three log orders more of hrR3 virions are produced from infection of colon carcinoma cells than from infection of normal hepatocytes in viral replication assays. This viral replication is oncolytic. A single intravascular administration of hrR3 into immune-competent mice bearing diffuse liver metastases dramatically reduces tumor burden. hrR3-mediated tumor inhibition is equivalent in immune-competent and immune-incompetent mice, suggesting that viral oncolysis and not the host immune response is the primary mechanism of tumor destruction. HSV1-mediated oncolysis of diffuse liver metastases is effective in mice preimmunized against HSV1. These results indicate that replication-competent HSV1 mutants hold significant promise as cancer therapeutic agents. Yoon, S. S., Nakamura, H., Carroll, N. M., Bode, B. P., Chiocca, E. A., Tanabe, K. K. An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma.
Key Words: HSV1 • gene therapy • ribonucleotide reductase
This article has been cited by other articles:
|
|
 |
|
  K. K. Tanabe, A. Lemoine, D. M. Finkelstein, H. Kawasaki, T. Fujii, R. T. Chung, G. Y. Lauwers, Y. Kulu, A. Muzikansky, D. Kuruppu, et al. Epidermal Growth Factor Gene Functional Polymorphism and the Risk of Hepatocellular Carcinoma in Patients With Cirrhosis JAMA, January 2, 2008; 299(1): 53 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Kuruppu, A.-L. Brownell, A. Zhu, M. Yu, X. Wang, Y. Kulu, B. C. Fuchs, H. Kawasaki, and K. K. Tanabe Positron Emission Tomography of Herpes Simplex Virus 1 Oncolysis Cancer Res., April 1, 2007; 67(7): 3295 - 3300. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Cross and J. K. Burmester Gene therapy for cancer treatment: past, present and future. Clin. Med. Res., September 1, 2006; 4(3): 218 - 227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kasuya, D. K. Kuruppu, J. M. Donahue, E. W. Choi, H. Kawasaki, and K. K. Tanabe Mouse Models of Subcutaneous Spleen Reservoir for Multiple Portal Venous Injections to Treat Liver Malignancies Cancer Res., May 1, 2005; 65(9): 3823 - 3827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. F. Stanziale, H. Petrowsky, P. S. Adusumilli, L. Ben-Porat, M. Gonen, and Y. Fong Infection with Oncolytic Herpes Simplex Virus-1 Induces Apoptosis in Neighboring Human Cancer Cells: A Potential Target to Increase Anticancer Activity Clin. Cancer Res., May 1, 2004; 10(9): 3225 - 3232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kasuya, T. M. Pawlik, J. T. Mullen, J. M. Donahue, H. Nakamura, S. Chandrasekhar, H. Kawasaki, E. Choi, and K. K. Tanabe Selectivity of an Oncolytic Herpes Simplex Virus for Cells Expressing the DF3/MUC1 Antigen Cancer Res., April 1, 2004; 64(7): 2561 - 2567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Wong, M.-K. Chan, Z. Yu, T. H. Kim, A. Bhargava, B. M. Stiles, B. C. Horsburgh, J. P. Shah, R. A. Ghossein, B. Singh, et al. Effective Intravenous Therapy of Murine Pulmonary Metastases with an Oncolytic Herpes Virus Expressing Interleukin 12 Clin. Cancer Res., January 1, 2004; 10(1): 251 - 259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Mullen and K. K. Tanabe Viral Oncolysis for Malignant Liver Tumors Ann. Surg. Oncol., July 1, 2003; 10(6): 596 - 605. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H Palmer, M.-J. Chen, and D. J Kerr Gene therapy for colorectal cancer Br. Med. Bull., December 1, 2002; 64(1): 201 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Fu and X. Zhang Potent Systemic Antitumor Activity from an Oncolytic Herpes Simplex Virus of Syncytial Phenotype Cancer Res., April 1, 2002; 62(8): 2306 - 2312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Mullen and K. K. Tanabe Viral Oncolysis Oncologist, April 1, 2002; 7(2): 106 - 119. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bergmann, I. Romirer, M. Sachet, R. Fleischhacker, A. Garcia-Sastre, P. Palese, K. Wolff, H. Pehamberger, R. Jakesz, and T. Muster A Genetically Engineered Influenza A Virus with ras-Dependent Oncolytic Properties Cancer Res., November 1, 2001; 61(22): 8188 - 8193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Nakamura, J. T. Mullen, S. Chandrasekhar, T. M. Pawlik, S. S. Yoon, and K. K. Tanabe Multimodality Therapy with a Replication-conditional Herpes Simplex Virus 1 Mutant that Expresses Yeast Cytosine Deaminase for Intratumoral Conversion of 5-Fluorocytosine to 5-Fluorouracil Cancer Res., July 1, 2001; 61(14): 5447 - 5452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Ward, M. L. Read, and L. W. Seymour Systemic circulation of poly(L-lysine)/DNA vectors is influenced by polycation molecular weight and type of DNA: differential circulation in mice and rats and the implications for human gene therapy Blood, April 15, 2001; 97(8): 2221 - 2229. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Pawlik, H. Nakamura, S. S. Yoon, J. T. Mullen, S. Chandrasekhar, E. A. Chiocca, and K. K. Tanabe Oncolysis of Diffuse Hepatocellular Carcinoma by Intravascular Administration of a Replication-competent, Genetically Engineered Herpesvirus Cancer Res., June 1, 2000; 60(11): 2790 - 2795. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ikeda, H. Wakimoto, T. Ichikawa, S. Jhung, F. H. Hochberg, D. N. Louis, and E. A. Chiocca Complement Depletion Facilitates the Infection of Multiple Brain Tumors by an Intravascular, Replication-Conditional Herpes Simplex Virus Mutant J. Virol., May 15, 2000; 74(10): 4765 - 4775. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
